Status:
COMPLETED
Antisecretory Factor in Primary Glioblastoma 1
Lead Sponsor:
Peter Siesjö
Collaborating Sponsors:
Region Skane
Lund University
Conditions:
Glioblastoma
Cerebral Edema
Eligibility:
All Genders
18-69 years
Phase:
PHASE1
PHASE2
Brief Summary
This is a non-randomised, open-label, single center-centre, Phase I-II study in patients with newly diagnosed glioblastoma. 5 patients with newly diagnosed glioblastoma are enrolled in the study and w...
Detailed Description
Glioblastoma (GBM) is the most common primary brain tumor and also has the worst prognosis with a mean survival time below 1 year and a 5-year survival rate of less than 2%. AF is a 41kilodalton endo...
Eligibility Criteria
Inclusion
- Pathology verified glioblastoma
- Age 18-69 years
- Surgical treatment-biopsy or resection.
- Scheduled full concomitant radiochemotherapy treatment with radiation (60 Gy) and temozolomide,
- Informed consent
Exclusion
- No informed consent
- Egg yolk allergy
Key Trial Info
Start Date :
September 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2021
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT04116138
Start Date
September 1 2019
End Date
March 31 2021
Last Update
April 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Neurosurgery
Lund, Sweden, 22185